NeRRe Therapeutics has set up a new entity around a drug which it believes could be an effective alternative to hormone replacement therapy for hot flashes that may rapidly reduce debilitating sleep disturbance.

Attempts at developing an effective therapy for PWS, and the abnormal desire for food associated with the rare disorder, have been fruitless but Levo Therapeutics' enthusiasm for LV-101 remains high, despite a Phase III setback.

Tecentriq is the only checkpoint inhibitor to get approval for first-line TNBC but failure in a second study for that indication will encourage rival Merck & Co with Keytruda nearing approval.